This contract expires in 293 days (Mar 31, 2027).
BAYER HEALTHCARE PHARMACEUTICALS INC - XOFIGO - RADIUM RA 223DICHLORIDE INJ
Key Details
Description
XOFIGO - RADIUM RA 223DICHLORIDE INJ
Context & Analysis
On Feb 25, 2026, Department of Veterans Affairs obligated $81,988.74 to BAYER HEALTHCARE PHARMACEUTICALS INC for xofigo - radium ra 223dichloride inj. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in DUBLIN, OH. The contract is scheduled through Mar 31, 2027 — approximately 10 months remaining. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.